Apolipoprotein A-IV expression in mouse liver enhances triglyceride secretion and reduces hepatic lipid content by promoting very low density lipoprotein particle expansion

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 11, 2013, Pages 2501-2508

  Verhague, Melissa A ^a   Cheng, Dongmei ^a   Weinberg, Richard B ^a   Shelness, Gregory S ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

apolipoprotein B; metabolic syndrome; nonalcoholic fatty liver disease; triglyceride; VLDL

Indexed keywords

APOLIPOPROTEIN A4; LIPID; STEROL REGULATORY ELEMENT BINDING PROTEIN 1A; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; FATTY LIVER; LIPID DIET; LIPID LIVER LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOLIPOPROTEIN B; METABOLIC SYNDROME; NONALCOHOLIC FATTY LIVER DISEASE; TRIGLYCERIDE; VLDL;

ANIMALS; APOLIPOPROTEINS A; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; FATTY LIVER; FEMALE; GENE EXPRESSION; LIPID METABOLISM; LIPOPROTEINS, VLDL; LIVER; MALE; MICE; MICE, KNOCKOUT; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIGLYCERIDES;

EID: 84887080826     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301948     Document Type: Article

References (58)

1. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519-1523.
2. Bellentani S, Marino M. Epidemiology and natural history of non-alcholoic fatty liver disease (NAFLD). Ann Hepatol. 2009;8(suppl 1):S4-S8.
3. Fisher EA, Ginsberg HN. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem. 2002;277:17377-17380.
4. Shelness GS, Ledford AS. Evolution and mechanism of apolipoprotein B-containing lipoprotein assembly. Curr Opin Lipidol. 2005;16:325-332.
5. Sundaram M, Yao Z. Intrahepatic role of exchangeable apolipoproteins in lipoprotein assembly and secretion. Arterioscler Thromb Vasc Biol. 2012;32:1073-1078.
6. Swaney JB, Braithwaite F, Eder HA. Characterization of the apolipopro-teins of rat plasma lipoproteins. Biochemistry. 1977;16:271-278.
7. Weisgraber KH, Bersot TP, Mahley RW. Isolation and characterization of an apoprotein from the d less than 1.006 lipoproteins of human and canine lymph homologous with the rat A-IV apoprotein. Biochem Biophys Res Commun. 1978;85:287-292.
8. Wu AL, Windmueller HG. Identifcation of circulating apolipoproteins synthesized by rat small intestine in vivo. J Biol Chem. 1978;253:2525-2528.
9. Green PH, Glickman RM, Riley JW, Quinet E. Human apolipopro-tein A-IV. Intestinal origin and distribution in plasma. J Clin Invest. 1980;65:911-919.
10. Kalogeris TJ, Rodriguez MD, Tso P. Control of synthesis and secretion of intestinal apolipoprotein A-IV by lipid. J Nutr. 1997;127:537S-543S.
11. Lu S, Yao Y, Meng S, Cheng X, Black DD. Overexpression of apolipopro-tein A-IV enhances lipid transport in newborn swine intestinal epithelial cells. J Biol Chem. 2002;277:31929-31937.
12. Lu S, Yao Y, Cheng X, Mitchell S, Leng S, Meng S, Gallagher JW, Shelness GS, Morris GS, Mahan J, Frase S, Mansbach CM, Weinberg RB, Black DD. Overexpression of apolipoprotein A-IV enhances lipid secretion in IPEC-1 cells by increasing chylomicron size. J Biol Chem. 2006;281:3473-3483.
13. Gallagher JW, Weinberg RB, Shelness GS. apoA-IV tagged with the ER retention signal KDEL perturbs the intracellular traffcking and secretion of apoB. J Lipid Res. 2004;45:1826-1834.
14. Weinberg RB, Gallagher JW, Fabritius MA, Shelness GS. ApoA-IV modulates the secretory traffcking of apoB and the size of triglyceride-rich lipoproteins. J Lipid Res. 2012;53:736-743.
15. Aalto-Setälä K, Bisgaier CL, Ho A, Kieft KA, Traber MG, Kayden HJ, Ramakrishnan R, Walsh A, Essenburg AD, Breslow JL. Intestinal expression of human apolipoprotein A-IV in transgenic mice fails to infuence dietary lipid absorption or feeding behavior. J Clin Invest. 1994;93:1776-1786.
16. Weinstock PH, Bisgaier CL, Hayek T, Aalto-Setala K, Sehayek E, Wu L, Sheiffele P, Merkel M, Essenburg AD, Breslow JL. Decreased HDL cholesterol levels but normal lipid absorption, growth, and feeding behavior in apolipoprotein A-IV knockout mice. J Lipid Res. 1997;38:1782-1794.
17. Simon T, Cook VR, Rao A, Weinberg RB. Impact of murine intestinal apo-lipoprotein A-IV expression on regional lipid absorption, gene expression, and growth. J Lipid Res. 2011;52:1984-1994.
18. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147-152.
19. Shimano H, Horton JD, Hammer RE, Shimomura I, Brown MS, Goldstein JL. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin Invest. 1996;98:1575-1584.
20. Horton JD, Shimano H, Hamilton RL, Brown MS, Goldstein JL. Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. J Clin Invest. 1999;103:1067-1076.
21. Johnson FL, St Clair RW, Rudel LL. Effects of the degree of saturation of dietary fat on the hepatic production of lipoproteins in the African green monkey. J Lipid Res. 1985;26:403-417.
22. Khatun I, Zeissig S, Iqbal J, Wang M, Curiel D, Shelness GS, Blumberg RS, Hussain MM. Phospholipid transfer activity of microsomal triglyc-eride transfer protein produces apolipoprotein B and reduces hepat-osteatosis while maintaining low plasma lipids in mice. Hepatology. 2012;55:1356-1368.
23. Nassir F, Xie Y, Patterson BW, Luo J, Davidson NO. Hepatic secretion of small lipoprotein particles in apobec-1-/-mice is regulated by the LDL receptor. J Lipid Res. 2004;45:1649-1659.
24. Millar JS, Cromley DA, McCoy MG, Rader DJ, Billheimer JT. Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339. J Lipid Res. 2005;46:2023-2028.
25. Cohen RD, Castellani LW, Qiao JH, Van Lenten BJ, Lusis AJ, Reue K. Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. J Clin Invest. 1997;99:1906-1916.
26. Ostos MA, Conconi M, Vergnes L, Baroukh N, Ribalta J, Girona J, Caillaud JM, Ochoa A, Zakin MM. Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-defcient mice. Arterioscler Thromb Vasc Biol. 2001;21:1023-1028.
27. Yao Y, Lu S, Huang Y, Beeman-Black CC, Lu R, Pan X, Hussain MM, Black DD. Regulation of microsomal triglyceride transfer protein by apo-lipoprotein A-IV in newborn swine intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2011;300:G357-G363.
28. Pan X, Munshi MK, Iqbal J, Queiroz J, Sirwi AA, Shah S, Younus A, Hussain MM. Circadian regulation of intestinal lipid absorption by apolipo-protein AIV involves forkhead transcription factors A2 and O1 and micro-somal triglyceride transfer protein. J Biol Chem. 2013;288:20464-20476.
29. Stan S, Delvin E, Lambert M, Seidman E, Levy E. Apo A-IV: an update on regulation and physiologic functions. Biochim Biophys Acta. 2003;1631:177-187.
30. Kalogeris TJ, Rodriguez MD, Tso P. Control of synthesis and secretion of intestinal apolipoprotein A-IV by lipid. J Nutr. 1997;127:537S-543S.
31. Kalogeris TJ, Fukagawa K, Tso P. Synthesis and lymphatic transport of intestinal apolipoprotein A-IV in response to graded doses of triglyceride. J Lipid Res. 1994;35:1141-1151.
32. Tso P, Balint JA, Bishop MB, Rodgers JB. Acute inhibition of intestinal lipid transport by Pluronic L-81 in the rat. Am J Physiol. 1981;241:G487-G497.
33. Koga S, Miyata Y, Funakoshi A, Ibayashi H. Plasma apolipoprotein A-IV levels decrease in patients with chronic pancreatitis and malabsorption syndrome. Digestion. 1985;32:19-24.
34. Williams SC, Grant SG, Reue K, Carrasquillo B, Lusis AJ, Kinniburgh AJ. cis-acting determinants of basal and lipid-regulated apolipoprotein A-IV expression in mice. J Biol Chem. 1989;264:19009-19016.
35. Langner CA, Birkenmeier EH, Ben-Zeev O, Schotz MC, Sweet HO, Davisson MT, Gordon JI. The fatty liver dystrophy (fd) mutation. A new mutant mouse with a developmental abnormality in triglyceride metabolism and associated tissue-specifc defects in lipoprotein lipase and hepatic lipase activities. J Biol Chem. 1989;264:7994-8003.
36. Williams SC, Bruckheimer SM, Lusis AJ, LeBoeuf RC, Kinniburgh AJ. Mouse apolipoprotein A-IV gene: nucleotide sequence and induction by a high-lipid diet. Mol Cell Biol. 1986;6:3807-3814.
37. Le Beyec J, Chauffeton V, Kan HY, Janvier PL, Cywiner-Golenzer C, Chatelet FP, Kalopissis AD, Zannis V, Chambaz J, Pinçon-Raymond M, Cardot P. The-700/-310 fragment of the apolipoprotein A-IV gene combined with the-890/-500 apolipoprotein C-III enhancer is suffcient to direct a pattern of gene expression similar to that for the endogenous apo-lipoprotein A-IV gene. J Biol Chem. 1999;274:4954-4961.
38. Archer A, Sauvaget D, Chauffeton V, Bouchet PE, Chambaz J, Pinçon-Raymond M, Cardot P, Ribeiro A, Lacasa M. Intestinal apolipoprotein A-IV gene transcription is controlled by two hormone-responsive elements: a role for hepatic nuclear factor-4 isoforms. Mol Endocrinol. 2005;19:2320-2334.
39. Vergnes L, Taniguchi T, Omori K, Zakin MM, Ochoa A. The apolipo-protein A-I/C-III/A-IV gene cluster: ApoC-III and ApoA-IV expression is regulated by two common enhancers. Biochim Biophys Acta. 1997;1348:299-310.
40. Lee JH, Giannikopoulos P, Duncan SA, Wang J, Johansen CT, Brown JD, Plutzky J, Hegele RA, Glimcher LH, Lee AH. The transcription factor cyclic AMP-responsive element-binding protein H regulates triglyceride metabolism. Nat Med. 2011;17:812-815.
41. Lee AH. The role of CREB-H transcription factor in triglyceride metabolism. Curr Opin Lipidol. 2012;23:141-146.
42. Lee MW, Chanda D, Yang J, Oh H, Kim SS, Yoon YS, Hong S, Park KG, Lee IK, Choi CS, Hanson RW, Choi HS, Koo SH. Regulation of hepatic gluconeogenesis by an ER-bound transcription factor, CREBH. Cell Metab. 2010;11:331-339.
43. Zhang K, Shen X, Wu J, Sakaki K, Saunders T, Rutkowski DT, Back SH, Kaufman RJ. Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic infammatory response. Cell. 2006;124:587-599.
44. Malmström R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Järvinen H, Shepherd J, Taskinen MR. Defective regulation of triglycer-ide metabolism by insulin in the liver in NIDDM. Diabetologia. 1997;40: 454-462.
45. Danno H, Ishii KA, Nakagawa Y, et al. The liver-enriched transcription factor CREBH is nutritionally regulated and activated by fatty acids and PPARalpha. Biochem Biophys Res Commun. 2010;391:1222-1227.
46. Wang Y, Tran K, Yao Z. The activity of microsomal triglyceride transfer protein is essential for accumulation of triglyceride within microsomes in McA-RH7777 cells. A unifed model for the assembly of very low density lipoproteins. J Biol Chem. 1999;274:27793-27800.
47. Kulinski A, Rustaeus S, Vance JE. Microsomal triacylglycerol transfer protein is required for lumenal accretion of triacylglycerol not associated with ApoB, as well as for ApoB lipidation. J Biol Chem. 2002;277: 31516-31525.
48. Hamilton RL, Wong JS, Cham CM, Nielsen LB, Young SG. Chylomicron-sized lipid particles are formed in the setting of apolipoprotein B def-ciency. J Lipid Res. 1998;39:1543-1557.
49. Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res. 2003;44:22-32.
50. Sundaram M, Zhong S, Bou Khalil M, Links PH, Zhao Y, Iqbal J, Hussain MM, Parks RJ, Wang Y, Yao Z. Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res. 2010;51:150-161.
51. Aalto-Setälä K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN, Breslow JL. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest. 1992;90:1889-1900.
52. Jong MC, Rensen PC, Dahlmans VE, van der Boom H, van Berkel TJ, Havekes LM. Apolipoprotein C-III defciency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J Lipid Res. 2001;42:1578-1585.
53. Duivenvoorden I, Teusink B, Rensen PC, Romijn JA, Havekes LM, Voshol PJ. Apolipoprotein C3 defciency results in diet-induced obesity and aggravated insulin resistance in mice. Diabetes. 2005;54:664-671.
54. Alexander CA, Hamilton RL, Havel RJ. Subcellular localization of B apo-protein of plasma lipoproteins in rat liver. J Cell Biol. 1976;69:241-263.
55. Olofsson SO, Asp L, Borén J. The assembly and secretion of apolipopro-tein B-containing lipoproteins. Curr Opin Lipidol. 1999;10:341-346.
56. Weinberg RB, Cook VR, DeLozier JA, Shelness GS. Dynamic interfacial properties of human apolipoproteins A-IV and B-17 at the air/water and oil/water interface. J Lipid Res. 2000;41:1419-1427.
57. Weinberg RB, Anderson RA, Cook VR, Emmanuel F, Denefe P, Hermann M, Steinmetz A. Structure and interfacial properties of chicken apolipo-protein A-IV. J Lipid Res. 2000;41:1410-1418.
58. Rosen MJ. Emulsifcation by surfactants. In: Rosen MJ, ed. Surfactants and Interfacial Phenomena. New York, NY: John Wiley & Sons, Inc; 2004:303-331.